@article{c6a5900a0cb24b60aaa99bf94f5d11f7,
title = "Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases",
abstract = "Background: Evidence regarding the risk of immunogenicity in patients with inflammatory bowel disease (IBD) who switched anti-tumor necrosis factor alpha (anti-TNFα) therapies to a subsequent anti-TNFα (either infliximab or adalimumab) is conflicting. We aimed to assess the risk of consecutive immunogenicity to anti-TNFα in a large cohort of patients. Methods: This was a multicenter retrospective study. Medical records of adult and pediatric IBD switchers who had pharmacokinetic data for both agents between 2014 and 2020 were retrieved. Data including age, sex, disease type, duration of therapies, and concomitant use of immunomodulators (IMMs) were recorded. Results: Overall, 164 patients were included [52% female; 88% Crohn{\textquoteright}s disease; mean age = 24.4 ± 14.6 years; 108 (66%) switched from infliximab to adalimumab and 56 (34%) vice versa]; 120 (73.1%) patients switched due to an immunogenic failure. Among patients switching therapy from infliximab to adalimumab due to an immunogenic failure immunogenicity to infliximab was significantly associated with consecutive immunogenicity to adalimumab (p = 0.026). Forthy four out of 120 patients (36.6%) with an immunogenic failure to the first anti-TNFα started an IMM with the second anti-TNFα. This combination with IMM was not associated with reduction of consecutive immunogenicity (p = 0.31), but it was associated with longer drug retention (p = 0.007). Multivariate analysis demonstrated that older age at second anti-TNFα, adjusted to the chronology of therapy and sex, was associated with increased immunogenicity to the second anti-TNFα. Conclusion: Patients with IBD who switch from infliximab to adalimumab following an immunogenic failure are at increased risk for consecutive immunogenicity to adalimumab. IMM use after a switch prolongs drug retention.",
keywords = "adalimumab, anti-TNF, antibodies, immunomodulators, infliximab",
author = "Henit Yanai and Bella Ungar and Uri Kopylov and Fischler, {Tali Sharar} and Biron, {Irit Avni} and Ollech, {Jacob E.} and Idan Goren and Manar Matar and Perets, {Tsachi Tsadok} and Raanan Shamir and Iris Dotan and Shira Amir and Amit Assa",
note = "Funding Information: The statistical analysis was performed by Dr Tomer Ziv (PhD), statistician, Tel Aviv University, Tel Aviv, Israel. The analyses of infliximab and adalimumab pharmacokinetics in Sheba Medical Center were performed by Miri Yavzori and Dr Orit Picard at the Sheba Gastroenterology Laboratory, Ramat Gan, Israel. The authors received no financial support for the research, authorship, and/or publication of this article. Funding Information: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: H.Y.: Consultation and lectures fees from Abbvie, Janssen, Neopharm Ltd., Pfizer, and Takeda, and research grants from Pfizer. R.S.: Research grants from Abbvie. A.A.: Consultation and lectures fees from Abbvie and Takeda, and research grants from Abbvie and Janssen. M.M. and S.A. have no financial conflicts of interest to declare. B.U.: Consultation and lectures fees from Abbvie, Takeda, Janssen, and Neopharm Ltd. U.K.: Consulting fees from Abbvie, Jannsen, Takeda, MSD, Pfizer, and Medtronic; honoraria for lectures from Abbvie, Jannsen, Takeda, MSD, Pfizer, and Medtronic; leadership or fiduciary role from Takeda; and research grants from Takeda, Jannsen, and Medtronic. I.G.: Research grants from Pfizer, and travel grants from ECCO and IOIBD. I.D.: Institutional research grants from Altman and Pfizer; consulting fees from Arena, Gilead, Cambridge Healthcare, Wild bio, Food industries organization, and Integra Holdings; honoraria for lectures from Janssen, Abbvie, Takeda, Pfizer, Genentech/Roche, Arena, Neopharm Ltd., Celltrion, Rafa Laboratories, Ferring, Falk Pharma, Nestle, Celgene/BMS, and Abbott; and participation on a Data Safety Monitoring Board or Advisory Board from spare consortium Janssen, Abbvie, Takeda, Pfizer, Genentech/Roche, Arena, Neopharm Ltd., Gilead, Galapagos, Celltrion, Sublimity, Wild bio, Athos therapeutics, Food industries organization, Celgene/BMS, and Abbott. TSF, IAB, JEO and TTP report no conflicts of interest Publisher Copyright: {\textcopyright} The Author(s), 2022.",
year = "2022",
month = jan,
day = "1",
doi = "10.1177/17562848211068659",
language = "English",
volume = "15",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
}